Abionyx Pharma partners with OLON to manufacture CER-001 validation batches for regulatory filing

PUBT · 2d ago
Abionyx Pharma partners with OLON to manufacture CER-001 validation batches for regulatory filing
  • Abionyx Pharma formed a strategic manufacturing partnership with CDMO OLON to prepare CER-001 for regulatory approval and commercial supply.
  • Initial scope covers production of two validation batches, a key step in the regulatory strategy for LCAT deficiency.
  • Work spans two OLON sites in France, covering cell-culture production of recombinant human apoA-I, complexation with phospholipids, fill-and-finish.
  • Deal also sets a longer-term manufacturing framework for potential market launch, with scale-up intended to support a larger sepsis program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abionyx Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261006736714) on October 07, 2026, and is solely responsible for the information contained therein.